If you are experiencing a medical emergency, contact emergency services immediately: Emergency contacts and medical assistance
Crisis Scenario 1 — Acute MS Relapse
A genuine MS relapse (new neurological symptoms lasting > 24 hours, not attributable to fever or infection) is clinically significant. Most are managed with high-dose IV methylprednisolone to shorten the relapse duration. Some are severe enough to require hospital admission.
Severe relapse — when to go to an emergency room: - Sudden significant visual loss (optic neuritis with severe acuity reduction) - Inability to walk or severe new limb weakness - Breathing difficulty (in severe cervical cord relapse) - Confusion or cognitive change - Bladder or bowel dysfunction with acute onset
Important distinction — relapse vs pseudo-relapse: A pseudo-relapse is a temporary worsening of old MS symptoms triggered by fever, infection, or heat, without new lesions. It is not treated with IV steroids — it resolves when the trigger is removed. Ask your neurologist: is this a real relapse or a pseudo-relapse?
What to do: 1. Contact your MS neurologist first if symptoms are not life-threatening. Many neurologists manage relapses with outpatient IV methylprednisolone (a brief infusion, not necessarily a hospital admission). 2. If symptoms are severe or your neurologist is unreachable, go to an emergency room. 3. Tell the treating team you have MS, your MS type, what DMT you are on, and when symptoms started. 4. Call your scheme pre-authorisation line for admission authorisation (48-hour retrospective window applies for emergencies).
Crisis Scenario 2 — Serious Reaction to Natalizumab (PML Risk)
Natalizumab (Tysabri) — a high-efficacy injectable DMT — carries a risk of progressive multifocal leukoencephalopathy (PML), caused by JC virus reactivation. PML is rare but life-threatening.
Warning signs (seek emergency care immediately): - Rapidly progressive neurological symptoms (weakness, cognitive decline, vision changes, personality change) - Symptoms appear different from or more severe than previous MS relapses - JC virus antibody status has become positive during natalizumab treatment
If PML is suspected: 1. Stop natalizumab immediately. Do not take the next dose. 2. Go to a neurologist or emergency room with neurology capacity. 3. Urgent brain MRI is required. 4. If confirmed, plasma exchange (PLEX) is sometimes used to rapidly clear natalizumab; this is high-acuity hospital care.
Crisis Scenario 3 — The Financial Crisis: Ocrelizumab and Scheme Funding
Your neurologist has recommended ocrelizumab. Your scheme says it requires exceptional needs authorisation. You are now navigating the most expensive coverage decision in private healthcare.
Let's focus on what we can control.
| Situation | What Applies |
|---|---|
| Scheme has exceptional needs pathway for ocrelizumab + SARAA neurologist motivation submitted | Full coverage likely after approval process. Timeline: 4–8 weeks typically. |
| Scheme does not fund ocrelizumab at all | Platform therapy is the CDL-funded alternative. The clinical adequacy of this must be discussed with your neurologist. |
| PPMS diagnosed: ocrelizumab is the ONLY approved treatment | Make the case formally: ocrelizumab for PPMS is clinically indicated with no CDL formulary alternative. Submit PMB dispute to scheme if refused. |
| Currently without medical aid | No viable private access to ocrelizumab (R180,000-R250,000/year OOP). Roche patient assistance programme may be available — ask your neurologist. Public sector neuro access via academic hospitals. |
The formal dispute pathway: If your scheme refuses ocrelizumab for PPMS (where no alternative exists), you have grounds for a PMB dispute. The CDL covers MS and requires appropriate treatment. Submit a formal complaint to your scheme in writing. If unresolved, escalate to the Council for Medical Schemes (CMS). Your neurologist's clinical motivation is essential.
In Hospital Right Now (Acute Relapse)
- Pre-authorise the admission within 48 hours of admission. 24-hour authorisation number is on the back of your medical aid card.
- Your treating neurologist will bill separately from the hospital. Ask whether they bill at scheme rate or above — this is where specialist shortfall occurs.
- If you have gap cover, notify your gap insurer of the admission and the treating neurologist's details.
- IV methylprednisolone is the standard relapse treatment — it is PMB-covered.
Gap Cover: What It Does and Doesn't Do for MS
| Scenario | Gap Cover Helps? |
|---|---|
| Platform DMT (interferon beta, oral) | NO — CDL-funded; little gap exposure on the medicine |
| Ocrelizumab OOP cost | NO — gap cover does not cover formulary exclusions |
| Acute relapse admission: neurologist shortfall | YES — neurologist billing above scheme rate |
| Natalizumab infusion reaction | LOW — usually managed as day case |
| Physiotherapy, OT, bladder management | NO — typically d2d benefits; not a gap cover function |
The bottom line for MS: Gap cover solves the wrong problem for most MS patients. The neurologist shortfall on a relapse admission is real but modest. The existential financial exposure is whether your scheme will fund high-efficacy DMT. That is a scheme formulary question — not solvable by gap cover. For MS, get the right scheme first. Then choose the plan. Then consider gap cover last.
Don't wait for a crisis to check your MS cover. Run your AURA check